Braeburn and Camurus begin enrolment in Phase III trial of CAM2038 to treat chronic low back pain

US-based Braeburn Pharmaceuticals and Swedish biotechnology firm Camurus has begun enrolling for its Phase III trial of CAM2038 in patients with moderate-to-severe chronic low back pain who are currently being treated with opioids.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news